K. Lheritier

2.2k total citations · 2 hit papers
48 papers, 705 citations indexed

About

K. Lheritier is a scholar working on Rheumatology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, K. Lheritier has authored 48 papers receiving a total of 705 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Rheumatology, 15 papers in Hematology and 13 papers in Pathology and Forensic Medicine. Recurrent topics in K. Lheritier's work include Urticaria and Related Conditions (17 papers), Autoimmune and Inflammatory Disorders Research (15 papers) and Autoimmune Bullous Skin Diseases (13 papers). K. Lheritier is often cited by papers focused on Urticaria and Related Conditions (17 papers), Autoimmune and Inflammatory Disorders Research (15 papers) and Autoimmune Bullous Skin Diseases (13 papers). K. Lheritier collaborates with scholars based in Switzerland, United States and Italy. K. Lheritier's co-authors include Simon Hill, Sibylle Haemmerle, Jean‐Jacques Wyndaele, Koremasa Hayama, Ana M. Giménez‐Arnau, Adam Reich, Vik Khullar, Kenneth Abrams, Marcus Maurer and Helen J. Lachmann and has published in prestigious journals such as New England Journal of Medicine, Journal of Allergy and Clinical Immunology and Annals of the Rheumatic Diseases.

In The Last Decade

K. Lheritier

43 papers receiving 687 citations

Hit Papers

Remibrutinib, a novel BTK inhibitor, demonstrates promisi... 2022 2026 2023 2024 2022 2025 25 50 75 100
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria
    2022 100 citations Marcus Maurer, William Berger et al. Journal of Allergy and Clinical Immunology profile →
  2. Remibrutinib in Chronic Spontaneous Urticaria
    2025 25 citations Martin Metz, Michihiro Hide et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. Lheritier Switzerland 14 309 228 224 212 128 48 705
Camelia Doina Vrabie Romania 9 281 0.9× 57 0.3× 76 0.3× 122 0.6× 10 0.1× 27 517
Santiago Mendizábal Spain 12 33 0.1× 87 0.4× 110 0.5× 238 1.1× 29 0.2× 30 589
Anabela Barcelos Portugal 13 389 1.3× 124 0.5× 75 0.3× 208 1.0× 3 0.0× 73 588
Eujin Park South Korea 14 28 0.1× 60 0.3× 227 1.0× 40 0.2× 12 0.1× 61 575
Antonio G. Tristano Venezuela 11 203 0.7× 73 0.3× 30 0.1× 65 0.3× 5 0.0× 25 454
J. Champigneulle France 13 402 1.3× 19 0.1× 131 0.6× 36 0.2× 23 0.2× 39 750
Ada Lo Schiavo Italy 16 320 1.0× 91 0.4× 30 0.1× 110 0.5× 19 0.1× 36 815
Carmine D’Urzo Italy 8 100 0.3× 164 0.7× 270 1.2× 58 0.3× 3 0.0× 15 505
Tarinee Manchana Thailand 15 176 0.6× 119 0.5× 54 0.2× 13 0.1× 44 0.3× 51 750
M. Gallazzi Italy 10 83 0.3× 28 0.1× 144 0.6× 28 0.1× 39 0.3× 17 499

Countries citing papers authored by K. Lheritier

Since Specialization
Citations

This map shows the geographic impact of K. Lheritier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Lheritier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Lheritier more than expected).

Fields of papers citing papers by K. Lheritier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Lheritier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Lheritier. The network helps show where K. Lheritier may publish in the future.

Co-authorship network of co-authors of K. Lheritier

This figure shows the co-authorship network connecting the top 25 collaborators of K. Lheritier. A scholar is included among the top collaborators of K. Lheritier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Lheritier. K. Lheritier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Metz, Martin, Bin Yang, Eric Boren, et al.. (2025). The Impact of Remibrutinib on Urticaria Control in Patients with Chronic Spontaneous Urticaria: Long-term Results from the REMIX-1/-2 Phase 3 Trials. Journal of Allergy and Clinical Immunology. 155(2). AB176–AB176. 1 indexed citations
2.
Metz, Martin, Michihiro Hide, Mark Lebwohl, et al.. (2025). Remibrutinib in Chronic Spontaneous Urticaria. New England Journal of Medicine. 392(10). 984–994. 25 indexed citations breakdown →
3.
Bérard, F., Sarbjit S. Saini, Ana M. Giménez‐Arnau, et al.. (2024). Fast symptom improvement and favorable safety profile with remibrutinib in chronic spontaneous urticaria: REMIX-1/-2 studies. Revue française d'allergologie. 64. 103855–103855.
4.
Saini, Sarbjit S., Ana M. Giménez‐Arnau, Michihiro Hide, et al.. (2023). FAST SYMPTOM IMPROVEMENT AND FAVORABLE SAFETY PROFILE WITH REMIBRUTINIB IN CHRONIC SPONTANEOUS URTICARIA: REMIX-1/-2 STUDIES. Annals of Allergy Asthma & Immunology. 131(5). S230–S230. 5 indexed citations
5.
Leflein, Jeffrey, Sibylle Haemmerle, K. Lheritier, et al.. (2023). Remibrutinib Improves Chronic Spontaneous Urticaria in Patients Irrespective of Previous Anti-IgE Treatment: Results From a Phase 2b Study. Journal of Allergy and Clinical Immunology. 151(2). AB131–AB131.
6.
Giménez‐Arnau, Ana M., Koremasa Hayama, Adam Reich, et al.. (2023). Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks. Journal of Allergy and Clinical Immunology. 153(2). 479–486.e4. 40 indexed citations
7.
Maurer, Marcus, William Berger, Ana M. Giménez‐Arnau, et al.. (2022). Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology. 150(6). 1498–1506.e2. 100 indexed citations breakdown →
8.
Maurer, Marcus, William Berger, Ana M. Giménez‐Arnau, et al.. (2021). Remibrutinib (LOU064) Versus Placebo in Patients with Chronic Spontaneous Urticaria: A Randomised, Double-Blind, Phase 2b Dose-Finding Study. SSRN Electronic Journal. 1 indexed citations
9.
Benedetti, Fabrizio De, Jordi Antón, Marco Gattorno, et al.. (2016). THU0569 Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes (Colchicine Resistant FMF, HIDS/MKD and TRAPS). Annals of the Rheumatic Diseases. 75. 397–398. 4 indexed citations
10.
Grom, Alexei A., Norman T. Ilowite, Virginia Pascual, et al.. (2015). Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab. Arthritis & Rheumatology. 68(1). 218–228. 86 indexed citations
11.
Ruperto, Nicolino, Isabelle Koné‐Paut, Bo Magnusson, et al.. (2014). Predictors of response in patients with active systemic JIA (SJIA) receiving canakinumab: an exploratory analysis of pooled 12-week data. Pediatric Rheumatology. 12(S1). 4 indexed citations
12.
Quartier, Pierre, Müferet Ergüven, Gerd Horneff, et al.. (2012). AB1186 IL-1beta inhibition with canakinumab in patients with systemic juvenile idiopathic arthritis: Efficacy and safety outcomes from a single-dose, placebo-controlled study. Annals of the Rheumatic Diseases. 71. 705–705. 2 indexed citations
13.
14.
Koné‐Paut, Isabelle, Helen J. Lachmann, Jasmin Kuemmerle‐Deschner, et al.. (2011). Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Research & Therapy. 13(6). R202–R202. 103 indexed citations
15.
16.
MacDonald, Thomas M., Jean‐Yves Reginster, Thomas Littlejohn, et al.. (2008). Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. Journal of Hypertension. 26(8). 1695–1702. 19 indexed citations
17.
Dwyer, Peter, Con Kelleher, Jay M. Young, et al.. (2008). Long‐term benefits of darifenacin treatment for patient quality of life: Results from a 2‐year extension study. Neurourology and Urodynamics. 27(6). 540–547. 16 indexed citations
18.
Hill, Simon, Mostafa Elhilali, R. J. Millard, et al.. (2007). Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study. Current Medical Research and Opinion. 23(11). 2697–2704. 26 indexed citations
19.
Haab, François, Jacques Corcos, Paul Siami, et al.. (2006). Long‐term treatment with darifenacin for overactive bladder: results of a 2‐year, open‐label extension study. British Journal of Urology. 98(5). 1025–1032. 38 indexed citations
20.
Hill, Simon, Vik Khullar, Jean‐Jacques Wyndaele, & K. Lheritier. (2005). Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. International Urogynecology Journal. 17(3). 239–247. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Camelia Doina Vrabie Breakdown of academic impact, for papers by Santiago Mendizábal Breakdown of academic impact, for papers by Anabela Barcelos Breakdown of academic impact, for papers by Eujin Park Breakdown of academic impact, for papers by Antonio G. Tristano Breakdown of academic impact, for papers by J. Champigneulle Breakdown of academic impact, for papers by Ada Lo Schiavo Breakdown of academic impact, for papers by Carmine D’Urzo Breakdown of academic impact, for papers by Tarinee Manchana Breakdown of academic impact, for papers by M. Gallazzi
Rankless by CCL
2026